Latest News

• share
• favorite_border

What and Why: Vision and Traumatic Brain Injury (TBI): A view toward therapeutics More than 75% of all TBI patients experience visual disorders, including double vision, light sensitivity, difficulty reading print and even vision loss. This interactive session will bring together some of the best minds studying TBI to discuss two important topics: what happens inside the head and eyes of a patient with TBI that leads to symptoms, and the scientific exploration that gives hope for treatments for the debilitating condition.

• share
• favorite_border

There is good news for frequent public speakers. New research shows that individuals have the ability to quickly and accurately identify a crowd’s general emotion as focused or distracted, suggesting that we can trust our first impression of a crowd’s mood. The paper,Mixed emotions: Sensitivity to facial variance in a crowd of faces was recently published in the Journal of Vision.

• share
• favorite_border

Scientists have good news for patients who suffer from currently untreatable dry age-related macular degeneration (dry AMD). In a new study, researchers identified a potential target for future therapies to slow the progression of the blinding condition. Published in Investigative Ophthalmology & Visual Science (IOVS), the findings indicate that treatments currently used for other conditions could also work for dry AMD.

• share
• favorite_border

To honor the memory of a longtime leader in glaucoma treatment and research, the ARVO Foundation for Eye Research will present the Dr. David L. Epstein Award. The new award — a $100,000 prize — was established by the late Dr. Epstein's family and will be presented annually to a senior-level glaucoma researcher at the ARVO Annual Meeting. The first award will be given at ARVO 2016 in Seattle, Wash.

• share
• favorite_border

A new study may have unlocked understanding of a mysterious part of the brain — with implications for neurodegenerative conditions such as Alzheimer’s. The results, published in Translational Vision Science & Technology (TVST), open up new areas of research in the pursuit of neuroprotective therapies

• share
• favorite_border

On May 7, researchers are reporting a case study in which viable Ebola virus was present in the eye’s aqueous humor — the clear fluid in the front of the eye, between the lens and the cornea — 10 weeks after the virus was no longer detectable in the patient’s blood.

• share
• favorite_border

Researchers have developed a drug-releasing implant that controls pain and inflammation, eliminating the need for eye drops following cataract surgery. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Doctors have developed a new treatment capable of halting the progression of keratoconus, a progressive eye disease that manifests in teenagers. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Researchers are studying ways to get a snapshot of all the genetic material that a single retina cell uses to make proteins, revealing the health of that eye cell. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

An FDA-approved oral medication, 4-phenylbutyrate (PBA), has been found to prevent vision loss in mice with Leber’s congenital amaurosis (LCA). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Researchers have developed a mobile app to quickly and conveniently evaluate people for strabismus, a condition involving misalignment of the eyes. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Preterm babies with retinopathy of prematurity (ROP) treated using bevacizumab, a growth inhibitor, have been found to have lower motor scores than babies treated with traditional laser ablation. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Nurses trained to deliver eye injections for patients with the wet form of age-related macular degeneration (AMD) administered the treatments as safely and effectively as doctors, according to a new study. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Researchers have developed a new computer model to describe how cholesterol deposits, known as drusen, behave in the retina in the dry form of age-related macular degeneration (AMD). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Scientists have found that baicalein significantly lowers eye pressure and may act as an all-natural treatment for glaucoma. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Scientists have produced crude 3D tissue structures from induced pluripotent stem (iPS) cells under current good manufacturing practices (cGMP), an important step for eventual large-scale use in human patients. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

L-DOPA, a routine drug taken by patients suffering from Parkinson’s disease, has been found to delay the onset of age-related macular degeneration (AMD). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Researchers have identified a new target for stopping the progressive death of cells in the eye that leads to vision loss in glaucoma. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.

• share
• favorite_border

Researchers have found that blocking the connections between cells in the retina can prevent toxins in one cell from spreading – and killing – its neighbors. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Col

• share
• favorite_border

A new study found that eye drops were just as effective as eye injections for treating the wet form of age-related macular degeneration (AMD). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.